Exclusive Look at Sentieon's TNscope

About this webinar

Recorded On: Wednesday, February 28, 2018

Cancer is a genomic disease where the accumulation of genetic mutations in somatic cells contributes to tumorigenesis and metastasis. Accurate characterization of somatic mutations in tumors is crucial for personalized cancer treatments in clinical care. In collaboration with Golden Helix, Sentieon Inc. provides industry-standard tools for processing next-generation sequencing data, including tools that match the somatic variant callers MuTect and MuTect2 with over 10x speedups, scalable multithreading, no downsampling and improved determinism. Sentieon has built upon these achievements with a newly released somatic variant caller, TNscope. TNscope uses an improved mathematical model to provide substantially better accuracy over MuTect2 along with additional variant annotations. We further improve TNscope’s accuracy with a random forest machine-learning model for candidate variant filtration, resulting in a highly accurate variant caller with a single ensemble quality score.

Watch on demand

Please enjoy this webcast recording. Should you have any questions about the content covered, please reach out to our team here.

Download the slide deck

To download a copy of the slides, click on the LinkedIn icon. This will redirect you to the SlideShare site. From there, you can clip your favorite slides or download the entire deck to your computer.

Love this webcast? Check out more!

Find out how Golden Helix software enables users to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.